Novacyt S.A. (CDI) (NCYT)

Sector:

Health Care

Index:

FTSE AIM All-Share

 48.50p
   
  • Change Today:
      0.000p
  • 52 Week High: 118.00p
  • 52 Week Low: 43.73p
  • Currency: UK Pounds
  • Shares Issued: 70.63m
  • Volume: 0
  • Market Cap: £34.25m
  • RiskGrade: 453
  • Beta: 1.21

Novacyt test for variants of concern included in NHS framework

By Josh White

Date: Monday 17 May 2021

LONDON (ShareCast) - (Sharecast News) - Clinical diagnostics company Novacyt announced on Monday that its 'SNPsig' SARS-CoV-2 polymerase chain reaction (PCR) genotyping portfolio has been included in the NHS England framework for detecting Covid-19 'variants of concern'.
The AIM-traded firm also announced the launch of two new PCR assays to detect SARS-CoV-2 variants of concern.

It explained that the national framework was for testing of all positive SARS-CoV-2 samples from NHS and high-throughput 'Lighthouse' laboratories in England.

SNPsig COVID-19 20I/501Y.V1 + E484K is a CE-marked assay to detect 20I/501Y.V1, the variant of concern originally identified in the UK, as well as VOC-21FEB-02 and all SARS-CoV-2 variants carrying the E484K escape mutation.

SNPsig SARS-CoV-2 E484K Easy, meanwhile, is a research-use-only, streamlined workflow solution for the detection of SARS-CoV-2 variants carrying the E484K escape mutation for use with the company's q32 rapid-PCR instrument.

That assay comes with pre-filled cassettes, and includes one pipetting step to decrease operator complexity and improve cycle times.

"We are very pleased to be included in NHS England's VoC Framework, which allows our SNPsig range of products to be used at any NHS and Lighthouse laboratories, subject to local verification, as we continue to support diagnostic testing across the UK, and globally, through our extensive portfolio," said chief executive officer Graham Mullis.

"We remain committed to developing new tests to match the rapid evolution of the SARS-CoV-2 virus with our real-time bioinformatics surveillance programme and accelerated product development.

"Our SNPsig portfolio for detecting variants of interest and variants of concern now includes 12 individual assays to support scientists and clinicians in the ongoing fight against Covid-19."

At 0859 BST, shares in Novacyt were up 8.38% at 438.93p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

NCYT Market Data

Currency UK Pounds
Share Price 48.50p
Change Today 0.000p
% Change 0.00 %
52 Week High 118.00p
52 Week Low 43.73p
Volume 0
Shares Issued 70.63m
Market Cap £34.25m
Beta 1.21
RiskGrade 453

NCYT Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
68.56% above the market average68.56% above the market average68.56% above the market average68.56% above the market average68.56% above the market average
77.14% above the sector average77.14% above the sector average77.14% above the sector average77.14% above the sector average77.14% above the sector average
Price Trend
39.88% below the market average39.88% below the market average39.88% below the market average39.88% below the market average39.88% below the market average
18.92% below the sector average18.92% below the sector average18.92% below the sector average18.92% below the sector average18.92% below the sector average
Income Not Available
Growth
70.52% below the market average70.52% below the market average70.52% below the market average70.52% below the market average70.52% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average

NCYT Dividends

No dividends found

Trades for --2024

Time Volume / Share Price
0 @ 0.000p

NCYT Key Personnel

CFO Steve Gibson

Top of Page